BENEFIT Extension Study

Bayer283 enrolled

Overview

To assess the long-term effects of early therapeutic intervention, i.e. within two years following a first clinical demyelinating event suggestive of MS.

Study Type

OBSERVATIONAL

Enrollment

283

Conditions

Multiple Sclerosis

Interventions

Interferon beta-1b (Betaseron, BAY86-5046)DRUG

Standard Therapy for Multiple Sclerosis

Eligibility

Sex: ALLMin age: 23 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All patients randomized and treated at least once in study 304747 Exclusion Criteria: * Medical, psychiatric or other conditions that compromise the patient's ability to understand the purpose of the study

Locations (18)

Unnamed facility

Many Locations, Austria

Unnamed facility

Many Locations, Belgium

Unnamed facility

Many Locations, Canada

Outcomes

Primary Outcomes

To obtain further clinical data of patients with a first demyelinating event suggestive of Multiple Sclerosis enrolled in the BENEFIT Study

Time frame: End of Study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.